Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.59 |
| ▸ | NOD1 | Q9Y239 | 5/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | GNPAT | O15228 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | FAAH | O00519 | 5/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2897531 | 1.00 | SLC6A5 (0.59) | SLC6A5NOD1ALDH1A1ABCC4MAPT | |
| SCHEMBL452803 | 0.91 | ABCC4 (0.56) | SLC6A5NOD1ALDH1A1ABCC4MAPT | |
| SCHEMBL452804 | 0.91 | ABCC4 (0.56) | SLC6A5NOD1ALDH1A1ABCC4MAPT | |
| SCHEMBL8254931 | 0.89 | NOD1 (0.64) | SLC6A5NOD1FAAHEPHX2 | |
| SCHEMBL5177232 | 0.88 | ALDH1A1 (0.51) | SLC6A5NOD1ALDH1A1ABCC4MAPT | |
| SCHEMBL7043975 | 0.88 | ALDH1A1 (0.51) | SLC6A5NOD1ALDH1A1ABCC4MAPT | |
| SCHEMBL6562048 | 0.86 | FNTA (0.56) | SLC6A5NOD1ALDH1A1ABCC4MAPT | |
| SCHEMBL8254595 | 0.84 | NOD1 (0.61) | SLC6A5NOD1GNPATFAAH | |
| SCHEMBL11856693 | 0.83 | PLA2G2A (0.50) | SLC6A5NOD1ALDH1A1ABCC4MAPT | |
| SCHEMBL2695672 | 0.83 | PLA2G2A (0.50) | SLC6A5NOD1ALDH1A1ABCC4MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2083844-B1 | HCV NS3 PROTEASE INHIBITORS | MERCK SHARP & DOHME (US) | 2013-11-27 | — | — | EP | disclosed |
| US-8377874-B2 | HCV NS3 protease inhibitors | MERCK SHARP & DOHME CORP. (US) | 2013-02-19 | — | — | US | disclosed |
| US-8377874-B2 | HCV NS3 protease inhibitors | MERCK SHARP & DOHME CORP. (US) | 2013-02-19 | — | — | US | disclosed |
| US-8377874-B2 | HCV NS3 protease inhibitors | MERCK SHARP & DOHME CORP. (US) | 2013-02-19 | — | — | US | disclosed |
| US-20100286185-A1 | HCV NS3 Protease Inhibitors | MERCK SHARP & DOHME LLC | 2010-11-11 | — | — | US | disclosed |
| US-20100286185-A1 | HCV NS3 Protease Inhibitors | MERCK SHARP & DOHME LLC | 2010-11-11 | — | — | US | disclosed |
| US-20100286185-A1 | HCV NS3 Protease Inhibitors | MERCK SHARP & DOHME LLC | 2010-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286185-A1 | HCV NS3 Protease Inhibitors | HAVCR2, GTF3C3, CTSC | SLC6A5 3854/4885NOD1 1125/4885ALDH1A1 1199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.